Quanterix Corp

Quanterix Corp develops and commercializes ultra-sensitive life science instruments, assay kits, and related services used to measure proteins and biomarkers in biological samples. Its portfolio includes Simoa-based instruments, consumables, and the Accelerator Laboratory service platform, with customers served through direct sales and distribution channels in North America, Europe, and other international markets.

−85,3 %

46,8 %

−77,1 %

+1,1 %

2.84

2.11

— Quanterix Corp
%
Instruments20% Analytical instruments used for proteomics, biomarker detection, and spatial biology workflows.
Consumables and assay kits55% Reagents, bead-based consumables, and assay kits used with installed instruments.
Services25% Accelerator Laboratory and other research or collaboration services.

Quanterix sells primarily to life science researchers, pharmaceutical and biotech companies, and clinical research...

  • Pharmaceutical and biotech R&Dprimary

    Buys instruments, consumables, and services for biomarker discovery and clinical research.

  • Academic and government researchprimary

    Uses Simoa systems and assays for basic and translational research applications.

  • Clinical research organizationssecondary

    Outsources specialized testing and laboratory services for sponsored studies.

  • Diagnostic and clinical partnerssecondary

    Evaluates assays and platforms for future diagnostic or LDT applications.

Quanterix operates with a global customer base, with a substantial share of revenue generated outside North America...

  • •Revenue is materially international, with customers outside North America
  • •Sales and support staff are concentrated in North America and Europe
  • •China and APAC are targeted for broader distribution and support coverage
  • •Manufacturing is split between in-house facilities and third-party partners
  • •International sales depend on distributors, local compliance, and service coverage

Quanterix is focused on expanding its installed base, launching new instruments and tests, and extending its platform...

01
Commercialize new instruments and assaysshort-term

New products are central to replacing aging systems and sustaining platform relevance.

02
Expand diagnostics and clinical applicationsmedium-term

Diagnostic use cases can broaden the addressable market beyond research customers.

03
Build international distribution coveragemedium-term

International markets are a meaningful source of growth and require local support.

04
Strengthen customer retention and installed-base utilizationshort-term

Consumables and service revenue depend on active instrument usage and repeat demand.

Quanterix faces competition from larger life science instrument companies and smaller specialists across proteomics,...

high

Competitive pressure from larger and specialized rivals

The company competes with firms such as Bio-Techne, 10x Genomics, Bruker, and others across multiple platforms.

Scope
proteomics, spatial biology, diagnostics
Materiality
high
high

Customer concentration

A meaningful portion of revenue comes from a limited number of large customers, increasing volatility if one reduces spend.

Scope
top customers and major pharma accounts
Materiality
high
high

Product development and launch delays

Technical challenges or supply chain issues could slow commercialization of next-generation instruments.

Scope
instrument refresh and new assays
Materiality
high
high

Acquisition integration and internal control risk

Integrating acquired businesses and remediating control weaknesses can create reporting and execution risk.

Scope
Akoya integration and financial reporting
Materiality
high
medium

International execution and compliance risk

Growth outside North America depends on distributors, foreign regulations, and anti-bribery compliance.

Scope
Europe, China, APAC
Materiality
medium
Revenue recognition across multiple revenue streams
Quarterly mix and timing can shift reported revenue materially
Acquisition accounting for Akoya and other deals
Can affect revenue, amortization, and impairment risk
Goodwill and intangible asset impairment
Potential non-cash charges if expected benefits do not materialize
Contingent consideration and fair value estimates
Can create earnings volatility through remeasurement

Quantum-Si Inc

QSI · Measuring & Controlling Devices, NEC

Onconetix, Inc.

ONCO · Pharmaceutical Preparations

STANDARD BIOTOOLS INC.

LAB · Pharmaceutical Preparations

BIOMERICA INC

BMRA · In Vitro & In Vivo Diagnostic Substances

QuidelOrtho Corp

QDEL · In Vitro & In Vivo Diagnostic Substances

BIODESIX INC

BDSX · Services-Medical Laboratories

: 29/04/2026